Tyrian Investments’s Teva Pharmaceuticals TEVA Stock Holding History

Tyrian Investments’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-44,491	Closed	-$2.05M	–	14
2016 Q3	$2.05M	Hold	44,491	–	–	0.79%	18
2016 Q2	$2.23M	Sell	44,491 -19,400	-30%	-$1.03M	2.27%	20
2016 Q1	$3.42M	Sell	63,891 -145,709	-70%	-$8.55M	1.48%	10
2015 Q4	$13.8M	Buy	+209,600	New	+$13M	4.14%	11

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Tyrian Investments's TEVA Position: Q4 2016 in Review

Tyrian Investments sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 44,491 shares — an estimated $2.05M sold.

Tyrian Investments first reported a position in TEVA in Q4 2015 and held it in 4 quarters. The position peaked at $13.8M in Q4 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Tyrian Investments reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Tyrian Investments sold 44,491 Teva Pharmaceuticals shares in Q4 2016, an estimated $2.05M.
Tyrian Investments first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 4 quarters.
Tyrian Investments's Teva Pharmaceuticals position peaked at $13.8M in Q4 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Tyrian Investments's 13F filing for Q4 2016.